Group 1 - The stock price of Chengda Pharmaceutical (301201) experienced significant fluctuations, with a single-day increase of 3.17% on February 12, 2026, and a total market capitalization of 6.351 billion yuan [1] - The market focus is on sectors such as cell immunotherapy, hepatitis concepts, and CRO concepts, which are driving investor interest [1] - On February 13, the stock continued its upward trend, closing at 41.67 yuan, reflecting a 1.51% increase from the previous day [1] Group 2 - Over the past 7 trading days (February 6 to February 13, 2026), the stock price rose from 38.05 yuan to 41.67 yuan, marking a cumulative increase of 9.51% with a volatility of 11.30% [2] - On February 12, there was a net inflow of 17.2629 million yuan from main funds, indicating a continuous increase in positions for two consecutive days [2] - As of February 11, the balance of margin financing and securities lending was 305 million yuan, showing a decrease of 0.42% from the previous day [2]

Core Insights - The report emphasizes the historical positioning of silver indicators, noting that 93% of historical dates are below 200%, while the current level exceeds 1800%, indicating potential price adjustments during the decline phase of silver [11] - It highlights the macroeconomic narratives, including geopolitical tensions and the impact of the new Federal Reserve chair, suggesting that the current market is less influenced by overseas factors [3][12] - The investment strategy focuses on three main areas: core growth assets, global competitive advantages, and emerging growth sectors, with specific recommendations for companies in these categories [14] Company Summaries TCL Electronics (01070) - TCL Electronics is forming a joint venture with Sony, where TCL will hold 51% and Sony 49%, aiming to leverage cost and technology advantages in the large-size and mini LED sectors [15] - The joint venture is expected to enhance TCL's high-end product series capabilities [15] Mao Geping (01318) - The brand is expanding its global presence with a new store in Hong Kong and a focus on integrating Eastern aesthetics with modern art, enhancing its international brand narrative [16] Anjuke Food (603345) - The company is shifting from a reliance on large B2B clients to a selective supermarket customization strategy, collaborating with major retailers to launch tailored products, resulting in a 28.1% year-on-year revenue increase in the supermarket channel [17] Chengda Pharmaceutical (301201) - Chengda is transitioning towards biocell therapy, developing innovative drug pipelines and forming strategic partnerships, including a significant collaboration with Chiron Pharma, which has led to clinical advancements [19] Xinquan Co., Ltd. (603179) - The company has established strong partnerships with major domestic truck manufacturers and is focused on expanding its automotive component offerings, leveraging over 20 years of industry experience [20] Jianghuai Automobile (600418) - Jianghuai is developing a new generation of high-end intelligent electric vehicles, integrating advanced technologies from partnerships with high-tech companies like Huawei [21] Chip Origin (688521) - The company reported significant growth in its chip design and mass production businesses, with a 290.82% quarter-on-quarter increase in design revenue and a 132.77% increase in mass production revenue [22] Tencent Holdings (00700) - Tencent's performance exceeded expectations with a 15.4% year-on-year revenue growth, driven by strong sales and R&D efficiency, leading to a notable increase in net profit [23] China Resources Land (01109) - The company is transitioning its real estate service platform to offer comprehensive lifecycle services, enhancing customer engagement through a new digital platform [24] China Merchants Energy Shipping (601872) - The company is benefiting from rising oil shipping rates, with Q4 2025 VLCC average rates reaching $94,000 per day, marking a significant increase in operational profits [26]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 财通证券发布研报称，化学原料药PPI长期承压，行业经历低谷。随着上游成本上涨、政策驱动出清， 以及GLP-1口服小分子、小核酸等新药产业化趋势成熟，头部原料药企业凭借卡位MNC供应链的核心优 势，有望从周期股转向创新产业链，开启第二增长曲线。 财通证券主要观点如下： 化学原料药PPI指数长期承压 过去几年，原料药行业经历了艰难时期。各类产品价格下跌，其中沙坦类、肝素类、动保类等价格已跌 至历史低位，部分龙头企业甚至处于亏损阶段。同时，集采对化药制剂的降价效应逐渐传递到上游原 料，而致原料药利润率不断下降。化学原料药PPI指数长期承压。 原料药企业有望开启第二增长曲线 投资建议：关注头部中间体、原料药及CDMO企业，建议关注诚达药业、联化科技、药明康德、凯莱 英、九州药业、奥锐特、天宇药业、康龙化成、博腾股份等。 风险提示：商业化不及预期的风险；贸易摩擦的风险；产能提升不及预期的风险。 原材料价格及汇率上涨，反内卷政策有望驱动原料药行业加速出清，同时，新兴产业趋势走向成熟，原 料药企业有望开启第二增长曲线。由于石油化工相关上游原料价格有上 ...

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

Industry Overview - The pharmaceutical and biotechnology sector experienced a decline of 0.39% last week, ranking 27th among 31 primary industries in the Shenwan index. The CSI 300 index fell by 0.62%, indicating that the pharmaceutical sector outperformed the CSI 300 by 0.23 percentage points [3] - The medical services sub-sector reported a drop of 2.17%, while other sub-sectors such as traditional Chinese medicine and medical commercial showed positive growth [3] Company Performance - Notable performers in the medical services sector included: - Nuohe Zhiyuan (+11.5%) - Xin Licheng (+9.4%) - Dian Diagnostics (+8.2%) - ST Zhongzhu (+7.1%) - Guangzheng Eye Hospital (+6.2%) - Underperformers included: - Boteng Co. (-6.9%) - Chengda Pharmaceutical (-6.6%) - WuXi AppTec (-6.4%) - Mediso (-4.8%) - Chengdu Xian Dao (-4.5%) [4] Financial Metrics - The medical services sector's Price-to-Earnings (PE) ratio is 35.30X, with a one-year maximum of 41.13X and a minimum of 28.46X. The Price-to-Book (PB) ratio stands at 3.58X, with a one-year maximum of 4.00X and a minimum of 2.48X. The PE ratio decreased by 0.85X and the PB ratio decreased by 0.09X compared to the previous week [6] CXO Industry Insights - The J.P. Morgan Healthcare Conference highlighted an optimistic outlook for the CXO industry, with companies like WuXi AppTec and WuXi Biologics showcasing strong growth prospects. The industry is transitioning from scale competition to value competition, focusing on advanced technologies and global supply chains. Notably, ADC CDMO is expected to drive significant revenue growth [7] Investment Recommendations - The report maintains a "buy" rating for the medical services sector, emphasizing the importance of innovation in the pharmaceutical supply chain. Key areas of focus include: - High growth: Companies involved in ADC CDMO and peptide CDMO, such as WuXi AppTec and Hao Yuan Pharmaceutical - Expected improvement: Third-party testing laboratories and consumer healthcare sectors, particularly in ophthalmology and dentistry, such as Aier Eye Hospital and Dian Diagnostics [8]

Core Viewpoint - Chengda Pharmaceutical (301201.SZ) expects a loss of 11 million to 18 million yuan in 2025, with a non-recurring loss of 27.5 million to 34.5 million yuan [1] Group 1: Financial Performance - The company has implemented effective sales strategies and steadily advanced market development, resulting in revenue growth during the reporting period [1] - Fixed asset scale has expanded due to the completion and delivery of fundraising projects, leading to increased depreciation and amortization expenses [1] Group 2: Investment and Development - The wholly-owned subsidiary, Shanghai Jiuqian Cheng Bio-pharmaceutical Co., Ltd., is still in the innovative drug research and development phase and has not yet generated revenue [1] - The company has conducted impairment tests on inventory and investment properties at the end of the reporting period, recognizing corresponding impairment provisions based on prudence [1]

南财智讯1月28日电，诚达药业发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为亏 损1100万元至1800万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为亏损2750 万元至3450万元。公司本报告期业绩变动的主要原因如下：1、报告期内，公司围绕既定发展战略，紧 密结合市场环境变化，制定并实施积极有效的销售策略，稳步推进市场开发与业务拓展工作，持续强化 核心经营能力，顺利实现营业收入的增长。2、随着募投项目完工交付，报告期内，公司固定资产规模 扩大，折旧摊销费用增加；全资孙公司上海玖乾诚生物医药有限公司尚处于创新药研发投入期，尚未产 生收入；同时基于谨慎性原则，公司对报告期期末的存货和投资性房地产进行了减值测试，并计提了相 应的减值准备，以上因素均对净利润造成不利影响。3、预计公司本报告期非经常性损益对净利润的影 响金额约1650万元，主要为计入当期损益的政府补助及现金管理投资收益等。综上所述，公司本报告期 仍处于亏损状态，但相较上年同期，亏损幅度有所收窄。 ...

证券代码：301201 证券简称：诚达药业 公告编号：2026-002 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预计情况：预计净利润为负值 单位：人民币万元 | 项目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司股东的净利润 | 亏损：1,100万元至1,800万元 | 亏损：2,810万元 | | 扣除非经常性损益后的净利润 | 亏损：2,750万元至3,450万元 | 亏损：5,767万元 | | 基本每股收益（元/股） | -0.0726元/股至-0.1188元/股 | -0.1849元/股 | 诚达药业股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 （一）业绩预告期间 3、预计公司本报告期非经常性损益对净利润的影响金额约1,650万元， 主要为计入当期损益的政府补助及现金管理投资收益等。 综上所述，公司本报告期仍处于亏损状态，但相较上年同期，亏损幅度 有所收窄。 四、其他相关说明 本次业绩预告是公司财务部门初步 ...

Group 1 - The global biotech and pharmaceutical investment and financing activities are expected to rebound significantly in 2025, driven by the robust development of innovative drug technology platforms, leading to a comprehensive recovery in the CXO industry and sustained industry prosperity into 2026 [1] - The Chinese CRO market is projected to return to a growth trajectory in 2025, with a notable 19% year-on-year increase in IND numbers and a substantial rise in BD transaction amounts, indicating a vibrant domestic innovative drug market [1] - The demand side globally is showing a strong rebound, establishing a solid foundation for growth, with biotech financing reaching a historical high in Q4 2025 and multinational pharmaceutical companies experiencing a recovery in demand [1] Group 2 - WuXi AppTec (药明康德) is expected to report impressive performance in 2025, with adjusted net profit increasing by 41.3%, driven by the TIDES business, which has seen revenue growth exceeding 90% [2] - WuXi Biologics has reached a record high of 945 projects, with a 30% growth in dual monoclonal and ADC projects, indicating a strong pipeline for future commercialization [2] - WuXi AppTec's subsidiary, WuXi STA, is focusing on the ADC/XDC sector, with revenue growth exceeding 40% in 2025 and an increase in global market share to over 24% [2] Group 3 - The Chinese clinical CRO market is at a clear turning point, with Tigermed (泰格医药) benefiting from the industry recovery, as order prices stabilize and the domestic clinical pipeline grows alongside improved financing conditions [3] Group 4 - Global CDMO giants are accelerating expansion, with optimistic performance guidance; Fujifilm is expected to secure $8 billion in new orders in 2025, reflecting strong demand for large molecule CDMO services [4] - Charles River anticipates an improvement in order trends starting in H2 2025, with a forecast for revenue growth in its safety assessment business by H2 2026, serving as an early indicator of recovery in the CXO industry [4] Group 5 - Investment recommendations include focusing on leading clinical CRO platforms like Tigermed and niche leaders such as Pruis, as well as front-end CRO companies with shorter order fulfillment cycles and greater marginal elasticity [5] - In the CDMO sector, attention is advised on leading companies in the peptide supply chain, ADC beneficiaries, and those with forward-looking layouts in small nucleic acids, as well as companies with significant potential for marginal traction from large products [5]

Group 1 - The core point of the article is that Chengda Pharmaceutical (301201.SZ) is currently experiencing a decline in stock price, with a closing price of 39.67 yuan and a drop of 4.16%, indicating that the stock is in a state of breaking its initial public offering (IPO) price [1] - Chengda Pharmaceutical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on January 20, 2022, with an initial public offering of 24,174,035 shares at a price of 72.69 yuan per share [1] - On its first day of trading, the stock reached a peak price of 188.00 yuan, which remains the highest point since its listing [1] Group 2 - The total amount raised from the IPO was 1,757.21 million yuan, with a net amount of 1,621.45 million yuan after deducting issuance costs [1] - The actual net fundraising amount exceeded the originally planned amount by 1,108.17 million yuan, with the initial target set at 513.28 million yuan for projects including "pharmaceutical intermediates, raw materials, and R&D center expansion" as well as "supplementing working capital" [1] - The total issuance costs for the IPO were 135.76 million yuan, with underwriting fees amounting to 117.93 million yuan [2] Group 3 - The actual controllers of Chengda Pharmaceutical are Ge Jianli, Lu Gang, and Lu Jin, with Lu Jin being a Chinese national who holds permanent residency in Canada [3] - On July 3, 2023, the company announced its 2022 annual equity distribution plan, which involves a cash distribution of 3.00 yuan for every 10 shares and a capital reserve increase of 6.00 shares for every 10 shares [3] - The record date for the equity distribution was set for July 6, 2023, with the ex-dividend date on July 7, 2023 [3]